Viridian Therapeutics, Inc.DE 10-K Cybersecurity GRC - 2024-02-27

Page last updated on April 11, 2024

Viridian Therapeutics, Inc.DE reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-02-27 16:34:18 EST.

Filings

10-K filed on 2024-02-27

Viridian Therapeutics, Inc.\DE filed an 10-K at 2024-02-27 16:34:18 EST
Accession Number: 0001590750-24-000007

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

ITEM 1C. CYBERSECURITY In the ordinary course of our business, we collect, use, store, and transmit digitally confidential, sensitive, proprietary, personal, and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and 70 manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by our information technology team, which is led by our Vice President, Digital Operations & Facilities, and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment. For example, we conduct cybersecurity audits, and ongoing risk assessments, including due diligence on and audits of our key technology vendors, CROs, and other contractors and suppliers. We also conduct periodic employee trainings on cyber and information security, among other topics. In addition, we consult with outside advisors and experts, when appropriate, to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company s risk environment. Our Vice President, Digital Operations & Facilities, who reports directly to the Chief Operating Officer and has over 12 years of experience managing information technology and cybersecurity matters, together with our senior leadership team, is responsible for assessing and managing cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework that is overseen by our Audit Committee of our board of directors and our board of directors. In the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. See Risk Factors for additional information on cybersecurity risks we face. Our board of directors, as a whole and at the Audit Committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. Our Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives biannual updates on cybersecurity and information technology matters and related risk exposures from our Chief Operating Officer as well as other members of the senior leadership team. The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.


Company Information

NameViridian Therapeutics, Inc.\DE
CIK0001590750
SIC DescriptionServices-Medical Laboratories
TickerVRDN - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30